Merck reported Q1 2026 revenue of $16.5 billion, a 5% increase compared to the first quarter of 2025. Non-GAAP EPS for the quarter was $2.10, representing a 4% year-over-year improvement. Revenue growth was primarily driven by continued expansion of Keytruda in early-stage oncology indications and the rapid commercial ramp-up of Winrevair following its successful launch. These gains were partially offset by lower sales of Lagevrio and the ongoing impact of foreign exchange headwinds on international vaccine sales.
Note: Merck's FY'25 ended on Dec 31, 2025. Q1 FY'26 ended on Mar 31, 2026.
The commercial launch of Winrevair has exceeded initial market expectations, establishing a significant new growth pillar for Merck's cardiovascular franchise. Following its FDA approval, the drug has seen strong physician uptake for the treatment of pulmonary arterial hypertension, supported by positive clinical data and favorable payer coverage. This strategic pivot into cardiovascular disease is a key component of Merck's effort to diversify its revenue base ahead of the late-decade patent expirations for its oncology portfolio.
Below are key drivers of Merck's value that present opportunities for upside or downside to the current Trefis price estimate:
For additional details, select a division from the interactive Trefis split for Merck at the top of the page.
Merck is a leading global biopharmaceutical company that develops innovative health solutions across prescription medicines, vaccines, and animal health products. The company focuses its research and development on therapeutic areas with high unmet needs, including oncology, infectious diseases, and cardiovascular conditions, while maintaining a significant presence in the global vaccine market.
The Oncology segment is the most significant contributor to Merck's valuation due to Keytruda's industry-leading sales volume and high operating margins.
Keytruda is the top-selling drug globally, with approvals for more than 30 indications. Its leadership in first-line lung cancer and its expansion into adjuvant settings provide a massive, stable patient base. This therapeutic dominance generates significant cash flow that Merck reinvests into its late-stage pipeline and strategic acquisitions.
Merck holds a leading position in the human vaccine market, anchored by the Gardasil franchise for HPV prevention. The high manufacturing complexity and significant regulatory hurdles for vaccines create a wide moat, protecting Merck from rapid generic erosion and ensuring long-term, high-margin revenue streams.
Merck Animal Health is one of the largest players in the veterinary medicine industry, providing a diversified revenue stream that is less affected by human drug pricing legislation. The division benefits from strong brand loyalty among veterinarians and a growing global trend in pet ownership and livestock productivity.
Merck is focused on mitigating the impact of the 2028 Keytruda patent cliff through targeted M&A. By acquiring assets in immunology and cardiovascular health, the company is building a diverse portfolio of next-generation biologics designed to sustain revenue growth as its flagship oncology product faces future biosimilar competition.
The company is prioritizing the development of subcutaneous and co-formulated drug delivery systems. This trend aims to improve patient convenience and treatment adherence while simultaneously creating new intellectual property layers that can extend the commercial lifecycle of its core biologic therapies.
Merck is actively managing the implications of the Medicare price negotiation framework. The company is shifting its R&D focus toward therapeutic areas and drug classes that offer better protection under current legislation, while also engaging in legal and advocacy efforts to shape the future of pharmaceutical pricing in the United States.
